Revenue: As of FY2025, the actual value is USD 4.092 B, beating the estimate of USD 4.088 B.EPS: As of FY2025, the actual value is USD 1.87, missing the estimate of USD 2.2109.EBIT: As of FY2025, the actual value is USD 782.9 M.<h3>CooperVision Segment</h3><ul><li>Net Sales: $2,743.8 million in 2025, a 5% increase from $2,609.4 million in 2024, driven by growth in toric and multifocal lenses, primarily through the success of Biofinity and MyDay, and sphere lenses, primarily through MiSight and MyDay.</li><li>Operating Income: $729.6 million in 2025, an 8% increase from $676.2 million in 2024, primarily due to the increase in net sales outpacing the increase in operating expenses.</li><li>SGA Expenses: $969.3 million in 2025, a 6% increase from $910.7 million in 2024, due to increased selling activities, severance costs, and long-lived asset write-offs.</li><li>R&amp;D Expenses: $91.3 million in 2025, a 10% increase from $82.9 million in 2024, focused on contact lenses and manufacturing technology.</li></ul><h3>CooperSurgical Segment</h3><ul><li>Net Sales: $1,348.6 million in 2025, a 5% increase from $1,286.0 million in 2024, with office and surgical net sales increasing due to Paragard contraceptive devices and the acquisition of obp Surgical, and fertility net sales increasing due to genomic and gamete services.</li><li>Operating Income: $43.4 million in 2025, a 63% decrease from $118.3 million in 2024, primarily due to inventory and long-lived asset write-offs, severance costs, and increased amortization expense.</li><li>SGA Expenses: $568.4 million in 2025, a 6% increase from $534.2 million in 2024, due to severance costs, increased selling activities, and long-lived asset write-offs.</li><li>R&amp;D Expenses: $80.9 million in 2025, a 12% increase from $72.2 million in 2024, focused on surgical devices and fertility solutions.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $796.1 million in 2025, an increase from $709.3 million in 2024, primarily due to changes in prepaid and other assets and an increase in non-cash add-back of long-lived asset write-offs.</li><li>Investing Cash Flow: -$372.9 million in 2025, a decrease from -$764.6 million in 2024, primarily due to $343.4 million cash paid for acquisitions in 2024.</li><li>Financing Cash Flow: -$425.9 million in 2025, primarily due to the repurchase of common stock, net repayments on the revolving credit, and the first installment payment related to the Cook Medical acquisition.</li></ul><h3>Outlook / Guidance</h3><ul><li>The company is optimistic about the long-term prospects for the worldwide contact lens and general health care markets, despite facing significant risks and uncertainties in the global operating environment, including economic conditions, regulatory developments, and supply chain disruptions.</li></ul>

Cooper Cos | 10-K: FY2025 Revenue Beats Estimate at USD 4.092 B